Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Once again, tomorrow's NEJM, a recurring feature. Two articles and an editorial once again highlight how complex medicine and cancer are in terms of my ability to report back to the board. That is to say- hard for me to grasp. Articles on the cancer genetics of lower grade gliomas and diffuse gliomas and the genomics of each class are presented in very careful detail. What the authors find is that various mutations are related to different histology and survival, not surprising really, but apparently this level of detail for brain tumors has not been known before. TP53 mutations occurred in many of the intermediate survival tumors for each study. for example, in one group of lower grade glioma patients, 94% had TP53 mutations. These patients survived for an average of 6 years.

These brain tumors sort themselves according to groups of mutations- not just one, but 2 or 3 for each group. To me this suggests a role for Kevetrin in a decent percentage of brain tumors, in concert with other drugs that target other genes/proteins- EGFR, HER2, etc

Look I am a novice about this stuff but again oncology moves toward genetics and away from histology and this will continue to point the way toward p53 agents playing a role in so many tumor types.